CL2019003503A1 - Composiciones sinérgicas que comprenden dimiracetam (r) (1) y dimiracetam (s) (2) en una proporción no racémica. - Google Patents

Composiciones sinérgicas que comprenden dimiracetam (r) (1) y dimiracetam (s) (2) en una proporción no racémica.

Info

Publication number
CL2019003503A1
CL2019003503A1 CL2019003503A CL2019003503A CL2019003503A1 CL 2019003503 A1 CL2019003503 A1 CL 2019003503A1 CL 2019003503 A CL2019003503 A CL 2019003503A CL 2019003503 A CL2019003503 A CL 2019003503A CL 2019003503 A1 CL2019003503 A1 CL 2019003503A1
Authority
CL
Chile
Prior art keywords
dimiracetam
prefensorable
disorder
composition
synergistic compositions
Prior art date
Application number
CL2019003503A
Other languages
English (en)
Inventor
Michael Scherz
Carlo Farina
Original Assignee
Metys Pharmaceuticals AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metys Pharmaceuticals AG filed Critical Metys Pharmaceuticals AG
Publication of CL2019003503A1 publication Critical patent/CL2019003503A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Detergent Compositions (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UNA COMPOSICIÓN DE ENANTIÓMEROS DE 3,6,7,7A-TETRAHIDRO-1H-PIRROLO[1,5-A]IMIDAZOL-2,5-DIONA Y SOLVATOS O CO-CRISTALES 10 FARMACÉUTICAMENTE ACEPTABLES DEL MISMO EN UNA CIERTA PROPORCIÓN, UNA COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE DICHA COMPOSICIÓN, SU USO COMO UN MEDICAMENTO Y EL USO DE LAS COMPOSICIONES INVENTIVAS O COMPOSICIONES FARMACÉUTICAS EN EL TRATAMIENTO Y/O PREVENCIÓN DE UNA ENFERMEDAD O TRASTORNO 15 SELECCIONADO GENERALMENTE Y PREFERIBLEMENTE DE NEUROPATÍA SENSORIAL PERIFÉRICA, PREFERIBLEMENTE DOLOR NEUROPÁTICO PERIFÉRICO; CONVULSIONES; DEPRESIÓN; O DETERIORO COGNITIVO.
CL2019003503A 2017-05-31 2019-11-29 Composiciones sinérgicas que comprenden dimiracetam (r) (1) y dimiracetam (s) (2) en una proporción no racémica. CL2019003503A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17173760 2017-05-31

Publications (1)

Publication Number Publication Date
CL2019003503A1 true CL2019003503A1 (es) 2020-04-24

Family

ID=59053899

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019003503A CL2019003503A1 (es) 2017-05-31 2019-11-29 Composiciones sinérgicas que comprenden dimiracetam (r) (1) y dimiracetam (s) (2) en una proporción no racémica.

Country Status (32)

Country Link
US (2) US10738054B2 (es)
EP (2) EP3534898B1 (es)
JP (2) JP6810983B2 (es)
KR (1) KR102269493B1 (es)
CN (1) CN110719779B (es)
AU (1) AU2018276382B2 (es)
BR (1) BR112019025006A2 (es)
CA (1) CA3061274C (es)
CL (1) CL2019003503A1 (es)
CO (1) CO2019013212A2 (es)
CY (1) CY1123386T1 (es)
DK (1) DK3534898T3 (es)
EA (1) EA201992817A1 (es)
EC (1) ECSP19085426A (es)
ES (1) ES2825498T3 (es)
GE (1) GEP20227336B (es)
HR (1) HRP20201608T1 (es)
HU (1) HUE050981T2 (es)
IL (1) IL270833B (es)
JO (1) JOP20190251A1 (es)
LT (1) LT3534898T (es)
MX (1) MX2019013897A (es)
NI (1) NI201900122A (es)
PE (1) PE20200699A1 (es)
PH (1) PH12019502580A1 (es)
PT (1) PT3534898T (es)
RS (1) RS60957B1 (es)
SG (1) SG11201909720SA (es)
SI (1) SI3534898T1 (es)
UA (1) UA125703C2 (es)
WO (1) WO2018219977A1 (es)
ZA (1) ZA201906863B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190251A1 (ar) * 2017-05-31 2019-10-21 Metys Pharmaceuticals AG تركيبات تآزرية تشتمل على (r)-ديميراسيتام (1) و(s)-ديميراسيتام (2) بنسبة غير راسيمية
ES2953785T3 (es) * 2018-12-04 2023-11-16 Metys Pharmaceuticals AG Composiciones sinérgicas que comprenden (R)-2-(2-oxopirrolidin-1-il)butanamida y (S)-2-(2-oxopirrolidin-1-il)butanamida en una proporción no racémica

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1233860B (it) 1988-02-08 1992-04-21 Isf Spa Derivati del peridroazacicloalca (1,2-a) imidazolo ad attivita' nootropa
US5200406A (en) 1988-02-08 1993-04-06 I.S.F. Societa Per Azioni Pharmaceutically useful 2,5-dioxo-1H-octahydroimidazo[1,2-A]azepines
GB9123641D0 (en) 1991-11-07 1992-01-02 Isf Spa Process
JP2002531431A (ja) 1998-12-02 2002-09-24 ダーウィン・ディスカバリー・リミテッド 治療用製品およびその使用
EP1034826A1 (en) 1999-03-05 2000-09-13 Reuter Chemische Apparatebau Co-crystallization process
ITMI20030573A1 (it) 2003-03-24 2004-09-25 Nikem Research Srl Composti ad azione nootropica, loro preparazione,
US20100048605A1 (en) * 2006-12-11 2010-02-25 University Of Kentucky Research Foundation Synergistic effects of combinations of nornicotine and opioids for the treatment of pain
AU2012201853B2 (en) 2007-04-16 2013-06-27 Neurotune Ag Use of dimiracetam in the treatment of chronic pain
ITMI20070770A1 (it) 2007-04-16 2008-10-17 Brane Discovery S R L Impiego di dimiracetam nel trattamento del dolore cronico
EP2215073A4 (en) 2007-10-31 2011-04-06 Merck Sharp & Dohme SLEEP MODULATION WITH NR2B RECEPTOR ANTAGONISTS
EP2098526B1 (en) 2008-02-22 2014-01-15 Neurotune AG Nitrogen-containing bicyclic compounds active on chronic pain conditions
US9125898B2 (en) 2008-11-14 2015-09-08 Neurotune Ag Acetam derivatives for pain relief
WO2012013640A1 (en) 2010-07-26 2012-02-02 Neurotune Ag Process for the preparation of dimiracetam
CA2828238A1 (en) 2010-10-29 2012-05-03 Neurotune Ag Therapeutic use of dimiracetam to prevent the hand & foot syndrome caused by sorafenib
WO2015010217A1 (en) 2013-07-24 2015-01-29 Neurotune Ag Dimiracetam in the treatment of depression
JOP20190251A1 (ar) * 2017-05-31 2019-10-21 Metys Pharmaceuticals AG تركيبات تآزرية تشتمل على (r)-ديميراسيتام (1) و(s)-ديميراسيتام (2) بنسبة غير راسيمية

Also Published As

Publication number Publication date
MX2019013897A (es) 2020-01-20
US20180346472A1 (en) 2018-12-06
AU2018276382A1 (en) 2019-10-31
CA3061274C (en) 2023-03-21
CN110719779A (zh) 2020-01-21
IL270833A (en) 2020-01-30
PH12019502580B1 (en) 2020-09-28
SG11201909720SA (en) 2019-11-28
DK3534898T3 (da) 2020-09-07
JOP20190251A1 (ar) 2019-10-21
HRP20201608T1 (hr) 2021-01-08
NZ758086A (en) 2020-12-18
JP6810983B2 (ja) 2021-01-13
KR102269493B1 (ko) 2021-06-25
CO2019013212A2 (es) 2020-01-17
NI201900122A (es) 2020-07-01
US10738054B2 (en) 2020-08-11
PH12019502580A1 (en) 2020-09-28
JP2021073171A (ja) 2021-05-13
PE20200699A1 (es) 2020-06-23
US20200331919A1 (en) 2020-10-22
CY1123386T1 (el) 2021-12-31
KR20200009093A (ko) 2020-01-29
GEP20227336B (en) 2022-01-10
RS60957B1 (sr) 2020-11-30
PT3534898T (pt) 2020-10-06
EP3534898B1 (en) 2020-08-05
IL270833B (en) 2021-05-31
EP3735971A1 (en) 2020-11-11
EP3534898A1 (en) 2019-09-11
LT3534898T (lt) 2020-12-10
JP7157471B2 (ja) 2022-10-20
CA3061274A1 (en) 2018-12-06
ECSP19085426A (es) 2020-05-29
EA201992817A1 (ru) 2020-04-06
JP2020521816A (ja) 2020-07-27
WO2018219977A1 (en) 2018-12-06
HUE050981T2 (hu) 2021-01-28
BR112019025006A2 (pt) 2020-06-16
ZA201906863B (en) 2021-02-24
CN110719779B (zh) 2022-02-01
AU2018276382B2 (en) 2021-03-25
SI3534898T1 (sl) 2020-11-30
UA125703C2 (uk) 2022-05-18
ES2825498T3 (es) 2021-05-17

Similar Documents

Publication Publication Date Title
UY38425A (es) Procesos novedosos para preparar n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1- isopropil-1h-pirazol-3-sulfonamida y sales de éste
CL2019002255A1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas.
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
CL2019003503A1 (es) Composiciones sinérgicas que comprenden dimiracetam (r) (1) y dimiracetam (s) (2) en una proporción no racémica.
EP4272832A3 (en) Antimicrobial compounds, compositions, and uses thereof
CO2022014499A2 (es) Moduladores de nlrp3
CL2017002229A1 (es) Inhibidores de bace1.
CL2019002020A1 (es) Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer.
BR112021000183A8 (pt) Preparação medicinal para uso externo
ECSP22092205A (es) Composición farmacéutica acuosa de levilimab y su uso
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
CO2021007055A2 (es) Composiciones sinérgicas que comprenden (r)-2-(2-oxopirrolidin-1-il)butanamida y (s)-2-(2-oxopirrolidin-1-il)butanamida en una proporción no racémica
DOP2021000069A (es) Derivados de 4 pirazin-2-ilmetil-morfolina y su uso como medicamento
MX2020004105A (es) Formulacion farmaceutica.
PH12021551239A1 (en) Synergistic compositions comprising r-2-(substituted-sulfonyl)-hexahydro-pyrrolo[1,2-a]pyrazin-6(2h)-ones and s-2-(substituted-sulfonyl)-hexahydro-pyrrolo[1,2-a]pyrazin-6(2h)-ones in a non-racemic ratio
ZA202311560B (en) Immediate release fixed-dose combination of memantine and donepezil
CO2024008068A2 (es) Producto de goma de mascar antiácida que no se traga, procedimiento para su preparación y usos del mismo
BR112022003500A2 (pt) Formulações líquidas de rifaximina
BR112021019999A2 (pt) Formulação de comprimido vaginal
UA109243U (uk) Тверда лікарська форма, що містить інгібітор віл протеази
UA113233U (uk) Пероральна фіксована комбінація теноксикаму і снодійного або заспокійливого компонента
EA201791798A1 (ru) Фармацевтические композиции, включающие n-(3,5-диметоксифенил)-n'-(1-метилэтил)-n-[3-(1-метил-1h-пиразол-4-ил)хиноксалин-6-ил]этан-1,2-диамин